Drreddys Laboratories | RDY - Ebitda

Keuangan

INR 13.75

INR 574.48B

INR 13.29B

Biaya Penjualan

INR 41.5B

INR 297.58B

Kewajiban Lancar

INR 154.49B

INR 72.29B

Dividen - Hasil

INR 0.66

INR 13.53B

INR 18.79B

INR 27.81K

Eps Laba Per Saham

INR 11.1

Modal Dan Cadangan

INR 389.37B

Laba Kotor Pada Penjualan

INR 45.2B

Beban Bunga Utang

INR 1.06B

Pendapatan Bunga

INR 919M

INR 11.69B

Kapitalisasi Pasar

INR 2.29B

Batas Pemasukan

INR 9.25B

Biaya Operasional

INR 73.9B

Laba Operasional

INR 12.81B

Modal Saham Biasa

INR 833.07M

Pe Harga Untuk Laba

28.78

Laba Sebelum Pajak

INR 12.28B

Pendapatan Penjualan

INR 86.71B

Beban Penjualan Dan Administrasi

INR 28.08B

INR 81.18B

Kreditur Perdagangan

INR 36.08B

Debitur Perdagangan

INR 101.4B

	Ebitda	Perubahan		Tanggal
ANI Pharmaceuticals	USD 71.6M		6.69M	2026-06
Aurora Cannabis	CAD 799K		2.9M	2026-06
Bayer	EUR 1.62B		529M	2026-09
Canopy Growth	CAD 8M		145M	2026-06
Cipla	INR 13.88B		154.2M	2026-09
Corcept Therapeutics	USD 42.16M		91.17M	2026-06
Drreddys Laboratories	INR 18.79B		10.16B	2026-09
GlaxoSmithKline	GBP 3.51B		734M	2026-06
Hikma Pharmaceutical	USD 369M		84M	2024-12
Lonza	CHF 1.01B		54M	2025-12
Novartis	USD 8.62B		2.14B	2026-09
Pacira	USD 48.67M		8.43M	2026-06
Phibro Animal Health	USD 68.1M		6.2M	2025-12
Prestige Brands	USD 61.24M		23.31M	2026-06
Richter Gedeon	HUF 90.34B		6.87B	2026-06
Sun Pharmaceuticals	INR 47.44B		3.26B	2026-09
Supernus Pharmaceuticals	USD 55.6M		24M	2026-09
Teva Pharmaceutical Industries	USD 1.5B		1.02B	2026-09